EP2968450A4 - MODIFIED TOXINS - Google Patents

MODIFIED TOXINS

Info

Publication number
EP2968450A4
EP2968450A4 EP14770668.3A EP14770668A EP2968450A4 EP 2968450 A4 EP2968450 A4 EP 2968450A4 EP 14770668 A EP14770668 A EP 14770668A EP 2968450 A4 EP2968450 A4 EP 2968450A4
Authority
EP
European Patent Office
Prior art keywords
modified toxins
toxins
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14770668.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2968450A2 (en
Inventor
Claude Geoffrey Davis
Deepshikha Datta
Matthew Paul Baker
Alyson Jane Rust
Simon Keen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ANGELICA THERAPEUTICS Inc
Original Assignee
ANGELICA THERAPEUTICS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANGELICA THERAPEUTICS Inc filed Critical ANGELICA THERAPEUTICS Inc
Publication of EP2968450A2 publication Critical patent/EP2968450A2/en
Publication of EP2968450A4 publication Critical patent/EP2968450A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP14770668.3A 2013-03-15 2014-03-11 MODIFIED TOXINS Withdrawn EP2968450A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361799910P 2013-03-15 2013-03-15
PCT/US2014/023761 WO2014150600A2 (en) 2013-03-15 2014-03-11 Modified toxins

Publications (2)

Publication Number Publication Date
EP2968450A2 EP2968450A2 (en) 2016-01-20
EP2968450A4 true EP2968450A4 (en) 2016-10-26

Family

ID=51581612

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14770668.3A Withdrawn EP2968450A4 (en) 2013-03-15 2014-03-11 MODIFIED TOXINS

Country Status (6)

Country Link
US (1) US10059750B2 (ja)
EP (1) EP2968450A4 (ja)
JP (1) JP2016519651A (ja)
CA (1) CA2902905A1 (ja)
HK (1) HK1220376A1 (ja)
WO (1) WO2014150600A2 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
US10642391B2 (en) * 2015-06-19 2020-05-05 Lg Electronics Inc. Touch panel and display device
EP3347056A4 (en) * 2015-09-11 2019-02-27 The Board of Trustees of the Leland Stanford Junior University BIOLOGICALLY RELEVANT ORTHOGONAL RECEPTOR / CYTOKINE PAIRS
WO2017147258A1 (en) * 2016-02-23 2017-08-31 Indiana University Research & Technology Corporation Emapii neutralizing antibody limits influenza a virus (iav)-induced lung injury
IL266696B2 (en) * 2016-12-22 2023-04-01 Cue Biopharma Inc Multimeric polypeptides modulate t cells and methods for their use
WO2018156465A1 (en) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
KR102619015B1 (ko) 2017-03-15 2023-12-28 큐 바이오파마, 인크. 면역 반응을 조절하는 방법
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3787673A4 (en) 2018-04-30 2022-04-27 Merck Sharp & Dohme Corp. METHODS FOR PRODUCING CAPSULAR CARRIER PROTEIN-POLYSACCHARIDE CONJUGATES OF STREPTOCOCCUS PNEUMONIAE
WO2019212844A1 (en) * 2018-04-30 2019-11-07 Merck Sharp & Dohme Corp. Methods for providing a homogenous solution of lyophilized mutant diptheria toxin in dimethylsulfoxide
CN111944036A (zh) * 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4143329A2 (en) * 2020-04-28 2023-03-08 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014835A2 (en) * 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4830962A (en) 1984-02-09 1989-05-16 Cetus Corporation Recombinant diphtheria toxin fragments
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US5792458A (en) 1987-10-05 1998-08-11 The United States Of America As Represented By The Department Of Health And Human Services Mutant diphtheria toxin conjugates
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
EP0362371A4 (en) 1988-04-15 1990-10-24 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DK0452484T3 (da) 1989-11-06 1996-10-14 Cell Genesys Inc Fremstilling af proteiner ved homolog rekombination
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
CA2076678C (en) 1990-03-02 1999-09-28 Diane Williams Improved chimeric toxins
WO1992006117A1 (en) 1990-09-28 1992-04-16 Seragen, Inc. Inhibiting unwanted immune responses
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5695983A (en) 1990-12-18 1997-12-09 The General Hospital Corporation Salmonella vaccines
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
EP0643559B1 (en) 1992-05-06 1999-04-14 The President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
DE69327534T2 (de) 1992-06-18 2000-06-08 Harvard College Impfstoffe gegen diphtherietoxin
US5856122A (en) 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin
DE69535002T2 (de) 1994-03-08 2006-12-07 Memorial Sloan-Kettering Cancer Center Rekombinante humanisierte antikörper gegen fb5
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
DE4430721A1 (de) 1994-08-30 1996-03-07 Hoechst Ag Autoglanztrocknungsmittel
US5843462A (en) 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
WO1998026078A1 (en) * 1996-12-09 1998-06-18 Genencor International, Inc. H mutant alpha-amylase enzymes
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US5976806A (en) 1997-06-25 1999-11-02 Pioneer Hi-Bred International, Inc. DNA ligase assay
US6835550B1 (en) 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US6960652B2 (en) 1999-03-30 2005-11-01 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
AU4057300A (en) 1999-03-30 2000-10-16 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinacious compounds
CA2386237A1 (en) 1999-10-04 2001-04-12 Twinstrand Therapeutics Inc. Improved ricin-like toxins for treatment of cancer
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
EP1252183B1 (en) 1999-12-02 2006-05-24 Thromb-X N.V. Method for reducing the immunogenicity of staphylokinase by elimination of t-cell epitopes
US20060018885A1 (en) 2000-11-14 2006-01-26 Ildstad Suzanne T Methods for increasing HSC graft efficiency
US20040256304A1 (en) 2001-01-19 2004-12-23 Perry Carlos V. Recirculating filter
WO2002062842A1 (en) 2001-02-06 2002-08-15 Merck Patent Gmbh Modified keratinocyte growth factor (kgf) with reduced immunogenicity
HUP0400698A3 (en) 2001-02-06 2006-01-30 Merck Patent Gmbh Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
BR0207015A (pt) 2001-02-06 2004-07-06 Merck Patent Ges Mit Beschroen Eritropoientina modificada (epo) com imunogenicidade reduzida
EP1392731B1 (en) 2001-02-06 2008-07-02 Merk Patent Gmbh Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
JP2004532618A (ja) 2001-02-06 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 低減された免疫原性を有する修飾されたレプチン
BR0207016A (pt) 2001-02-06 2004-02-03 Merck Patent Gmbh Fator neurotrófico derivado de cérebro humano modificado (bdnf) com imunogenicidade reduzida
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
JP2004532620A (ja) 2001-02-19 2004-10-28 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 免疫原性の低減された人工タンパク質
KR20030074839A (ko) 2001-02-19 2003-09-19 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 항-ｅｇｆｒ 항체
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
KR20030077632A (ko) 2001-02-26 2003-10-01 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 트롬보포이에틴
RU2003129056A (ru) 2001-03-02 2005-04-20 Мерк Патент ГмбХ (DE) Модифицированный интерферон альфа с уменьшенной иммуногенностью
CA2439682A1 (en) 2001-03-02 2002-09-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity
CN1494430A (zh) 2001-03-08 2004-05-05 Ĭ��ר�����޹�˾ 免疫原性减弱的经修饰鱼精蛋白
PL362986A1 (en) 2001-03-08 2004-11-15 Merck Patent Gmbh Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity
KR20030084992A (ko) 2001-03-15 2003-11-01 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 인터페론 베타
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20020197278A1 (en) 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
MXPA03012030A (es) 2001-06-26 2005-07-01 Agen Biomedical Ltd Anticuerpos humanizados derivados de dd-3b6/22, especificos para el fragmento de dimero d de fibrina.
HUP0400340A2 (hu) 2001-07-13 2004-08-30 Merck Patent Gmbh. Polipeptidek immunogenitásának csökkentésére szolgáló eljárások
HUP0402334A3 (en) 2001-09-04 2007-03-28 Merck Patent Gmbh Modified human growth hormone
PL369065A1 (en) 2001-09-04 2005-04-18 Merck Patent Gmbh Modified factor ix
ATE469176T1 (de) 2001-11-12 2010-06-15 Merck Patent Gmbh Modifizierter anti-tnf antikörper
US20050074863A1 (en) 2001-11-29 2005-04-07 Koen Hellendoorn T-cell epitodes in carboxypeptidase g2
WO2003084996A2 (en) 2002-04-09 2003-10-16 Merck Patent Gmbh Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
CN1646564A (zh) 2002-04-18 2005-07-27 默克专利有限公司 修饰的因子ⅷ
US20050181459A1 (en) 2002-06-11 2005-08-18 Matthew Baker Method for mapping and eliminating T cell epitopes
US20040018568A1 (en) 2002-07-23 2004-01-29 Subhashis Banerjee Methods for detecting deantigenized T cell epitopes and uses thereof
ES2310684T3 (es) 2002-08-09 2009-01-16 Merck Patent Gmbh Epitopes de celulas t en eritropoyetina.
AU2003266289A1 (en) 2002-08-21 2004-03-11 Merck Patent Gmbh T-cell epitopes in staphylococcal enterotoxin b
AU2003302986A1 (en) 2002-12-13 2004-07-09 Aurelium Biopharma Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
EP1581904A2 (en) 2003-01-08 2005-10-05 Xencor, Inc. Novel proteins with altered immunogenicity
US7619070B2 (en) 2003-04-23 2009-11-17 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
DK1636261T3 (da) 2003-06-26 2007-11-12 Merck Patent Gmbh Thrombopoietinproteiner med forbedrede egenskaber
EP1636267A2 (en) 2003-06-26 2006-03-22 MERCK PATENT GmbH Modified hirudin proteins and t-cell epitopes in hirudin
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
US20050176028A1 (en) 2003-10-16 2005-08-11 Robert Hofmeister Deimmunized binding molecules to CD3
EP1694706B1 (en) 2003-11-01 2012-04-04 Merck Patent GmbH Modified anti-cd52 antibody
US7431720B2 (en) 2003-11-25 2008-10-07 Ethicon, Inc. Multi-function clamping device with stapler and ablation heads
WO2005052129A2 (en) 2003-11-25 2005-06-09 Anjin Corporation Diptheria toxin variant
US20050153872A1 (en) 2004-01-12 2005-07-14 Xiao-Qing Qiu Methods and compositions for the treatment of infection
US20060228404A1 (en) 2004-03-04 2006-10-12 Anderson Daniel G Compositions and methods for treatment of hypertrophic tissues
DK1737961T3 (da) 2004-03-19 2013-08-05 Merck Patent Gmbh Modificerede bouganin proteiner, cytotoxiner og fremgangsmåder og anvendelser deraf
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
US20080085261A1 (en) 2004-10-19 2008-04-10 Haynes Barton F Vaccine Adjuvant
US20060165687A1 (en) 2004-10-19 2006-07-27 Duke University Vaccine adjuvant
CN1314806C (zh) 2005-01-14 2007-05-09 四川大学 小型化抗eb病毒肿瘤多肽及其应用与制备方法
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
US20060269514A1 (en) 2005-05-27 2006-11-30 Abdul-Rahman Jazieh Methods and compositions for the modulation of immune responses and cancer diseases
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
US20070250652A1 (en) 2006-04-24 2007-10-25 Atmel Corporation High speed dual-wire communications device requiring no passive pullup components
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014835A2 (en) * 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins

Also Published As

Publication number Publication date
JP2016519651A (ja) 2016-07-07
CA2902905A1 (en) 2014-09-25
US20160009768A1 (en) 2016-01-14
WO2014150600A3 (en) 2015-05-28
US10059750B2 (en) 2018-08-28
WO2014150600A8 (en) 2015-10-15
WO2014150600A2 (en) 2014-09-25
HK1220376A1 (zh) 2017-05-05
EP2968450A2 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
HK1220376A1 (zh) 修飾的毒素
DK3088517T3 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
DK3354246T3 (en) Udstyrsmonteringssystem
DK3077519T3 (en) Cmv-vacciner
HUE041397T2 (hu) Arilkinazolinok
HK1219427A1 (zh) 複合物
GB201409640D0 (en) Quick-coupler
DK3470074T3 (en) Probiotika
AU353575S (en) Stamphousing
DK3056208T3 (en) Immunpotentiator
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
DK2989854T3 (en) Strømstyret opvarmningssystem
AU4899P (en) Herbie53 Iresine herbstii
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
GB201421602D0 (en) Zielfernrohr
AU353331S (en) Kettlebell
AU353329S (en) Kettlebell
AU353325S (en) Kettlebell
AU353326S (en) Kettlebell
AU353327S (en) Kettlebell
AU353328S (en) Kettlebell
AU353330S (en) Kettlebell
GB201318786D0 (en) Gtifrsfaapp
GB201318654D0 (en) Holdlock

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151130

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160926

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/20 20060101ALI20160920BHEP

Ipc: C07K 16/32 20060101ALI20160920BHEP

Ipc: C07K 14/34 20060101ALI20160920BHEP

Ipc: A61K 45/06 20060101ALI20160920BHEP

Ipc: A61K 38/16 20060101AFI20160920BHEP

Ipc: A61K 39/00 20060101ALI20160920BHEP

Ipc: A61K 39/395 20060101ALI20160920BHEP

Ipc: C07K 14/55 20060101ALI20160920BHEP

Ipc: A61K 39/39 20060101ALI20160920BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1220376

Country of ref document: HK

17Q First examination report despatched

Effective date: 20181211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190622

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1220376

Country of ref document: HK